Skip to content
Contact Us
24 24

Experts in the Intricacies of Cell Therapy Development

End-to-end experience in delivering a broad range of cell therapies Contact us

Precision was born from a desire to support innovators in precision medicine. Your cell therapy project will be enriched by our collective experience in cell therapy development. Our services span from award-winning CRO to comprehensive biomarker assay services to pioneering builds of GMP compliant cell therapy facilities from 5000 to 500,000 square feet.

40. Human cells under a microscope

Helping innovators deliver on the promise of cell therapy

Cell therapy development is at the forefront of advanced therapeutic modalities, especially in oncology research, but the intricacies can complicate the development process.

Precision’s experience developing a broad range of cell therapies, including CAR T cells, stem cells, autologous and allogeneic products, and tumor-infiltrating lymphocytes, gives us insight into the challenges of cell therapy as a whole, as well as how development of each of these cell types differ. We understand the isues each program can face and our integrated, multidisciplinary team can create a bespoke solution appropriate for your project. We are working with leaders in cell therapy innovation and take pride in the FDA approvals we’ve supported. Bringing breakthrough treatments to patients in need is our purpose and passion.

25 countries with cell therapy trials
10 cell, gene and novel therapies industrialized
11 worldwide labs with PBMC processing
20 cell therapy trials in the last 5 years

A precise and integrated approach to cell therapy development.

Specialized capabilities and proven expertise in cell therapy development helps compress timelines and find efficiencies in every stage. When your team is collaborating under one global roof, you find ways to work smarter and bring novel therapies to market faster.

  • Explore
    clinical-laboratory-support

    Clinical Trial Design

    • Full service CRO for global trials
    • Patient recruitment and enrollment: specialization in rare disease
    • Expertise with current regulatory environment
    • Operational excellence in cell therapy study conduct
    Explore
  • Explore

    Specialty Lab Services

    • Immune Monitoring
    • Bioanalysis
    • Genomics
    • IHC/mIF and Pathology
    • Liquid Biopsy
    Explore
  • Explore
    manufacturing

    Manufacturing Solutions

    • End-to-end services for the entire manufacturing life cycle
      • Planning and designing
      • Building and testing
      • Deploying and operating
      • Scalability and flexibility
    Explore
  • Explore
    biospecimens

    Biospecimens

    • PBMCs—healthy and disease state
    • Leukopaks
    • Mobilized leukopaks
    Explore
  • Explore
    sample-processing

    PBMC & Sample Processing

    Sample processing with expertise in PBMC isolations from labs across 5 continents

    Explore
  • Explore
    commercialization

    CDx Development & Commercialization

    • Biomarker discovery and assay development
    • Preclinical planning and strategy
    • Assay development into single-site PMA CDx with full regulatory and market support
    Explore

Expertise in cell therapy trials

For cell therapy trials there is a keen demand for high-quality, efficient, well-run studies that enable teams to move rapidly in an iterative development cycle. Our experienced team recognizes the nuances involved and prepares trial strategies that address safety, site selection, training, patient recruitment and logistics. 

Explore

Scientific capabilities support cell therapies in the lab

Precision supports cell therapy development with a complete suite of biomarker assay services including assay development, validation and implementation to support every phase of your cell therapy project. Our team includes thought leaders in immunogenicity testing that are helping shape the regulatory landscape.

Explore

shot of sterile pharmaceutical manufacturing laboratory

Industrializing novel and complex therapies

Precision has vast experience in designing and building GMP-compliant cell and gene therapy facilities, using cutting-edge modular, emerging bioreactor, and single-use technologies. Our manufacturing playbook—which has been used by the leading cell and gene therapy organizations—has led to the development of the largest and most mature ATMP manufacturing footprint in the world.

6

in tech ops capital investments being managed

New Research Insights Into Cell Therapy

Discover all our brochures
eBook

Evolutions in Oncology Cell Therapy

Download eBook
Evolutions in Oncology Cell Therapy

Top leadership ratings for a CRO in the ISR Report 2024

  • CROLeadership2024Compatability
  • CROLeadership2024Capabilities
  • CROLeadership2024Reliability
  • CROLeadership2024Quality
  • CROLeadership2024Expertise

Our latest insights on cell therapy development

Discover
Read: FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma

Oncology - Cell Therapies

FDA Approves Breakthrough Cell Therapy for Synovial Sarcoma

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778887, hs_child_table_id=0, hs_updated_at=1715690972359, hs_published_at=1739807653319, description=Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines., avatar=Image{width=720,height=829,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/AndyKinley_headshot.png',altText='AndyKinley_headshot',fileId=167369936018}, linkedin=https://www.linkedin.com/in/andy-kinley-phd-5759551, hs_name=, hs_path=, lastname=Kinley, hs_initial_published_at=1716212769184, hs_created_at=1709645745118, hs_is_edited=false, hs_deleted_at=0, name=Andy, job=, slug=andy-kinley, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Andy Kinley avatar

    Andy Kinley
Discover
Read: Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint

Manufacturing - Cell Therapies - Gene Therapies

Navigating Cell and Gene Therapy Acquisitions: A Strategic Blueprint

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164426546550, hs_child_table_id=0, hs_updated_at=1716454235474, hs_published_at=1739807653319, description=Groundbreaking biotech entrepreneur, executive, and investor, dedicated to delivering transformative treatments to the patients who need them. Pioneered the industrialization of advanced therapeutics, including some of the earliest commercially approved cell and gene therapies, radioligand treatments, RNA-based therapies, and cutting-edge biologics. Created the leading global biologics and advanced therapy engineering consulting firm and developed the largest cell and gene therapy manufacturing footprint in the world. Deeply committed to advancing next-generation medicines, serves on multiple boards, philanthropic organizations, and patient-advocacy groups, including IQHQ, Alliance for Regenerative Medicines, and Alliance for mRNA Medicines., avatar=Image{width=720,height=812,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Anshul-Mangal.png',altText='Anshul-Mangal',fileId=167370347684}, linkedin=https://www.linkedin.com/in/amangal/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Mangal, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169484118, hs_is_edited=false, hs_deleted_at=0, name=Anshul, job=President, Manufacturing Solutions, slug=anshul-mangal, hs_updated_by_user_id=9297597}, second={hs_id=164426546553, hs_child_table_id=0, hs_updated_at=1716454239819, hs_published_at=1739807653319, description=Life sciences leader who helped pioneer the industrialization of biologics and advanced therapies. Deep expertise in small and large molecules, honed through work with a range of life science organizations, from start-ups and academic centers to financial institutions and CMOs/CROs. Spearheaded significant global turnkey facility builds, automation, validation, engineering, and serialization track and trace, deploying billions in capital across the life sciences sector. Led the creation of the Advanced Therapy Manufacturing Playbook which has helped develop the world’s largest advanced therapy manufacturing footprint. Actively serves on multiple boards including academic, philanthropic, biotech, and financial investment institutions., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Tony%20Khoury.webp',altText='Tony Khoury',fileId=165893018152}, linkedin=https://www.linkedin.com/in/tony-khoury-7470755/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Khoury, hs_initial_published_at=1713174153602, hs_created_by_user_id=62155952, hs_created_at=1713169549303, hs_is_edited=false, hs_deleted_at=0, name=Tony, job=Executive Vice President, Manufacturing Solutions, slug=tony-khoury, hs_updated_by_user_id=9297597}, third={}})
  • Anshul M. avatar

    Anshul M.
  • Tony K. avatar

    Tony K.
Discover
Read: Clinical Trial Trends: Cell Therapies Clinical Trial Landscape: Cell Therapies

Clinical Trials - Cell Therapies

Clinical Trial Trends: Cell Therapies

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778887, hs_child_table_id=0, hs_updated_at=1715690972359, hs_published_at=1739807653319, description=Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines., avatar=Image{width=720,height=829,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/AndyKinley_headshot.png',altText='AndyKinley_headshot',fileId=167369936018}, linkedin=https://www.linkedin.com/in/andy-kinley-phd-5759551, hs_name=, hs_path=, lastname=Kinley, hs_initial_published_at=1716212769184, hs_created_at=1709645745118, hs_is_edited=false, hs_deleted_at=0, name=Andy, job=, slug=andy-kinley, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Andy Kinley avatar

    Andy Kinley
Discover